331 related articles for article (PubMed ID: 28599954)
1. CMV-specific T-cell immunity in solid organ transplant recipients at low risk of CMV infection. Chronology and applicability in preemptive therapy.
Mena-Romo JD; Pérez Romero P; Martín-Gandul C; Gentil MÁ; Suárez-Artacho G; Lage E; Sánchez M; Cordero E
J Infect; 2017 Oct; 75(4):336-345. PubMed ID: 28599954
[TBL] [Abstract][Full Text] [Related]
2. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
[TBL] [Abstract][Full Text] [Related]
3. Impact of pretransplant CMV-specific T-cell immune response in the control of CMV infection after solid organ transplantation: a prospective cohort study.
Molina-Ortega A; Martín-Gandul C; Mena-Romo JD; Rodríguez-Hernández MJ; Suñer M; Bernal C; Sánchez M; Sánchez-Céspedes J; Pérez Romero P; Cordero E
Clin Microbiol Infect; 2019 Jun; 25(6):753-758. PubMed ID: 30292792
[TBL] [Abstract][Full Text] [Related]
4. Kinetic of the CMV-specific T-cell immune response and CMV infection in CMV-seropositive kidney transplant recipients receiving rabbit anti-thymocyte globulin induction therapy: A pilot study.
Martín-Gandul C; Pérez-Romero P; Mena-Romo D; Molina-Ortega A; González-Roncero FM; Suñer M; Bernal G; Cordero E;
Transpl Infect Dis; 2018 Jun; 20(3):e12883. PubMed ID: 29570917
[TBL] [Abstract][Full Text] [Related]
5. Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy.
Martín-Gandul C; Pérez-Romero P; Blanco-Lobo P; Benmarzouk-Hidalgo OJ; Sánchez M; Gentil MA; Bernal C; Sobrino JM; Rodríguez-Hernández MJ; Cordero E;
Transpl Int; 2014 Oct; 27(10):1060-8. PubMed ID: 24964364
[TBL] [Abstract][Full Text] [Related]
6. Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.
San-Juan R; Navarro D; García-Reyne A; Montejo M; Muñoz P; Carratala J; Len O; Fortun J; Muñoz-Cobo B; Gimenez E; Eworo A; Sabe N; Meije Y; Martín-Davila P; Andres A; Delgado J; Jimenez C; Amat P; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Aguado JM;
Transpl Infect Dis; 2015 Oct; 17(5):637-46. PubMed ID: 26134282
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
[TBL] [Abstract][Full Text] [Related]
8. Prospective Assessment of Cytomegalovirus Immunity in High-Risk Donor-Seropositive/Recipient-Seronegative Liver Transplant Recipients Receiving Either Preemptive Therapy or Antiviral Prophylaxis.
Limaye AP; Green ML; Edmison BC; Stevens-Ayers T; Chatterton-Kirchmeier S; Geballe AP; Singh N; Boeckh M
J Infect Dis; 2019 Jul; 220(5):752-760. PubMed ID: 31112280
[TBL] [Abstract][Full Text] [Related]
9. Pretransplant CD8 T-cell response to IE-1 discriminates seropositive kidney recipients at risk of developing CMV infection posttransplant.
López-Oliva MO; Martinez V; Buitrago A; Jiménez C; Rivas B; Escuin F; Santana MJ; Selgas R; Bellón T
Transplantation; 2014 Apr; 97(8):839-45. PubMed ID: 24345896
[TBL] [Abstract][Full Text] [Related]
10. Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment.
Fernández-Ruiz M; Giménez E; Vinuesa V; Ruiz-Merlo T; Parra P; Amat P; Montejo M; Paez-Vega A; Cantisán S; Torre-Cisneros J; Fortún J; Andrés A; San Juan R; López-Medrano F; Navarro D; Aguado JM;
Clin Microbiol Infect; 2019 Mar; 25(3):381.e1-381.e10. PubMed ID: 29803844
[TBL] [Abstract][Full Text] [Related]
11. Specific Immunity to Cytomegalovirus in Pediatric Cardiac Transplantation.
Jacobsen MC; Manunta MDI; Pincott ES; Fenton M; Simpson GL; Klein NJ; Burch M
Transplantation; 2018 Sep; 102(9):1569-1575. PubMed ID: 29509573
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection.
Chiereghin A; Potena L; Borgese L; Gibertoni D; Squarzoni D; Turello G; Petrisli E; Piccirilli G; Gabrielli L; Grigioni F; Lazzarotto T
J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29305542
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia.
Lisboa LF; Kumar D; Wilson LE; Humar A
Transplantation; 2012 Jan; 93(2):195-200. PubMed ID: 22179399
[TBL] [Abstract][Full Text] [Related]
14. Analysis of spontaneous resolution of cytomegalovirus replication after transplantation in CMV-seropositive patients with pretransplant CD8+IFNG+ response.
Páez-Vega A; Poyato A; Rodriguez-Benot A; Guirado L; Fortún J; Len O; Abdala E; Fariñas MC; Cordero E; de Gracia C; Hernández D; González R; Torre-Cisneros J; Cantisán S; ;
Antiviral Res; 2018 Jul; 155():97-105. PubMed ID: 29782877
[TBL] [Abstract][Full Text] [Related]
15. Evaluation and significance of cytomegalovirus-specific cellular immune response in lung transplant recipients.
Costa C; Astegiano S; Terlizzi ME; Sidoti F; Curtoni A; Solidoro P; Baldi S; Bergallo M; Cavallo R
Transplant Proc; 2011 May; 43(4):1159-61. PubMed ID: 21620077
[TBL] [Abstract][Full Text] [Related]
16. CMV-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study.
Sund F; Lidehäll AK; Claesson K; Foss A; Tötterman TH; Korsgren O; Eriksson BM
Clin Transplant; 2010; 24(3):401-9. PubMed ID: 19222507
[TBL] [Abstract][Full Text] [Related]
17. Pre-transplant assessment of pp65-specific CD4 T cell responses identifies CMV-seropositive patients treated with rATG at risk of late onset infection.
López-Oliva MO; Martínez V; Rodríguez-Sanz A; Álvarez L; Santana MJ; Selgas R; Jiménez C; Bellón T
Clin Immunol; 2020 Feb; 211():108329. PubMed ID: 31891764
[TBL] [Abstract][Full Text] [Related]
18. Assessing the risk of CMV reactivation and reconstitution of antiviral immune response post bone marrow transplantation by the QuantiFERON-CMV-assay and real time PCR.
Krawczyk A; Ackermann J; Goitowski B; Trenschel R; Ditschkowski M; Timm J; Ottinger H; Beelen DW; Grüner N; Fiedler M
J Clin Virol; 2018; 99-100():61-66. PubMed ID: 29331844
[TBL] [Abstract][Full Text] [Related]
19. Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients.
Banas B; Böger CA; Lückhoff G; Krüger B; Barabas S; Batzilla J; Schemmerer M; Köstler J; Bendfeldt H; Rascle A; Wagner R; Deml L; Leicht J; Krämer BK
BMC Immunol; 2017 Mar; 18(1):15. PubMed ID: 28270092
[TBL] [Abstract][Full Text] [Related]
20. Effect of delaying prophylaxis against CMV in D+/R- solid organ transplant recipients in the development of CMV-specific cellular immunity and occurrence of late CMV disease.
San-Juan R; Navarro D; García-Reyne A; Montejo M; Muñoz P; Carratala J; Len O; Fortun J; Muñoz-Cobo B; Gimenez E; Eworo A; Sabe N; Meije Y; Martin-Davila P; Andres A; Delgado J; Jimenez C; Amat P; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Aguado JM; ;
J Infect; 2015 Nov; 71(5):561-70. PubMed ID: 26183297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]